Enhancing peripheral clearance of beta amyloid as a treatment for Alzheimers disease

增强β淀粉样蛋白的外周清除作为阿尔茨海默病的治疗

• 批准号: nhmrc : 595300
• 负责人: Kevin Taddei
• 金额: $ 36.59万
• 依托单位: Edith Cowan University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/enhancing-peripheral-clearance-alzheimers-disease/95020
• 关键词: Enhancing; peripheral; clearance; beta; amyloid

Amyloid-beta (abeta) accumulation in the brain is a key step in the development of Alzheimer's disease, with potential therapies focusing on its clearance. Compounds that bind abeta in blood have been shown to alter brain abeta levels. We will assess the efficacy of a novel abeta-binding peptide to promote peripheral clearance of brain-derived abeta in a mouse model of AD. Such a drug would be effective in sporadic AD, where the efflux transport, clearance and degradation systems are defective.

淀粉样β（abeta）在大脑中的积累是阿尔茨海默病发展的关键步骤，潜在的治疗方法集中在其清除上。结合血液中abeta的化合物已被证明会改变大脑中的abeta水平。我们将评估一种新的abeta结合肽在AD小鼠模型中促进脑源性abeta的外周清除的功效。这样的药物在散发性AD中是有效的，其中外排转运、清除和降解系统是有缺陷的。